The study was aimed to know the pharmacokinetic interactions between moxifloxacin and pyrazinamide and also the pharmokinetic interactions between moxifloxacin and ethambutol and to know about the clinical significance. The study population was 12 healthy male volunteers, the duration of study was 13 days for each healthy volunteer and period of study was one year and it was a randomized open labelled non comparative prospective study. The pharmacokinetic variables were calculated based on plasma concentration of moxifloxacin alone and in combination with pyrazinamide and also in combination with ethambutol at different points from 0 -12 hours. The steady state mean pharmacokinetic variables such as peak concentration (Cmax), time at which Cmax is attained (Tmax), area under curve (AUC), clearance (Cl) and half-life (t1/2) were calculated and statistical analysis was done using student ‘t’ test and considered significant (P = < 0.05). The study concluded that there are no pharmocokinetic interactions between moxifloxacin and pyrazinamide and between moxifloxacin and ethambutol. Hence Moxifloxacin can be administered along with pyrazinamide and ethambutol for better patient compliance, increased cure rates and to reduce the duration of the anti-tuberculosis treatment.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
